Stephanie Trunk’s Insights

317 total results. Page 20 of 27.

Health Care Counsel Blog
OIG Report Highlights Impact of Improper Drug Classification
News
Stephanie Trunk Quoted on PhRMA Drug Pricing Lawsuit in Bloomberg BNA
Health Care Counsel Blog
PhRMA Challenges Constitutionality of California’s New Drug Pricing Transparency Law
Alerts
FTC Holds Public Workshop to Consider If Hatch-Waxman Is Working for Prescription Drug Competition
Health Care Counsel Blog
HOPPS 2018 Final Rule Released, Confirming Changes to Medicare Part B Drug Reimbursement for Drugs Purchased Under the 340B Program
Health Care Counsel Blog
California Passes Drug Transparency Law with Onerous Reporting Requirements for Manufacturers
Alerts
FDA Requires Pharma Companies to Certify Drug Listing Info
Health Care Counsel Blog
Uncertainty Becomes the Norm…for 340B Rulemaking, at Least
Health Care Counsel Blog
HOPPS Proposed Rule Recommends Big Changes to 340B Program
Health Care Counsel Blog
FDA Issues Draft Guidance For Product Identifier Requirements
Alerts
Sweeping Nevada Law to Impact Manufacturers, PBMs, Pharma Sales Representatives, and Nonprofit Organizations
Health Care Counsel Blog
Pharma Industry Take Note: Maryland Passed Price-Gouging Prohibition